Nitrofurantoin Monohydrate

Indications and usage: Nitrofurantoin monohydrate/macrocrystals capsules are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus . Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.

Mechanism of Action The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules. As a result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. Nitrofurantoin is bactericidal in urine at therapeutic doses.

With Biphasic clearance with 5–14 hr terminal t½ under Nitrofurantoin Monohydrate maintenance residence kinetics and Systemic oral bioavailability of roughly 70%–82% following first-pass transit bioavailability, Nitrofurantoin Monohydrate undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (nitrofurantoin monohydrate) and establishes therapeutic activity over initial pharmacodynamic onset within 1–2 hrs (peak cmax) for nitrofurantoin monohydrate.

Standard adult regimens span 25 mg/1 / 75 mg/1 Capsule, 75 mg/1 / 25 mg/1 Capsule, 25mg/5mL Bottle of Suspension. Prescribers screen specifically against treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug.; documented intolerance or hypersensitivity reaction involving nitrofurantoin monohydrate (nitrofuran antibacterial), while community micro-logs most frequently note diarrhea (10.1% of reports), nausea (8% of reports), somnolence (7.8% of reports).